Information:
Fel:
ID
14002
Beskrivning
GRASPA Treatment for Patients With Acute Myeloblastic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01810705
Länk
https://clinicaltrials.gov/show/NCT01810705
Nyckelord
Versioner (1)
- 2016-03-21 2016-03-21 -
Uppladdad den
21 mars 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Acute Myeloid Leukemia NCT01810705
Eligibility Acute Myeloid Leukemia NCT01810705
- StudyEvent: Eligibility
Similar models
Eligibility Acute Myeloid Leukemia NCT01810705
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Age
Item
Patient over 65 years old and less than 85 years old
boolean
C0001779 (UMLS CUI [1])
AML or myelodysplastic syndrome
Item
Newly diagnosed acute myeloid leukemia or post myelodysplastic syndrome diagnosed in the 6 months prior study enrollment
boolean
C0023467 (UMLS CUI [1])
C3463824 (UMLS CUI [2])
C3463824 (UMLS CUI [2])
Unfit for intensive chemotherapy
Item
unfit for intensive chemotherapy (at risk to suffer treatment related pejorative toxicities /early death) or patient unwilling to receive intensive chemotherapy
boolean
C3665472 (UMLS CUI [1])
WHO performance status scale
Item
who performance status ≤2 and estimated life expectancy ≥ 3 months
boolean
C1298650 (UMLS CUI [1])
Cytarabine treatment
Item
eligible to receive low-dose cytarabine treatment
boolean
C0010711 (UMLS CUI [1])
Postmenopausal state
Item
Evidence of post-menopausal status for female (absence of menstruation for 12 months)
boolean
C0232970 (UMLS CUI [1])
Acute Promyelocytic Leukemia
Item
Patients with m3 aml of french american british classification ( acute promyelocytic leukemia)
boolean
C0023487 (UMLS CUI [1])
Aml involving chromosome 16
Item
Patients with aml involving chromosome 16 abnormalities or translocation (8:21)
boolean
C3688691 (UMLS CUI [1])
Pancreatitis or thromboembolic event
Item
history of grade 3-4 pancreatitis or grade 3-4 thromboembolic event
boolean
C0030305 (UMLS CUI [1])
C0040038 (UMLS CUI [2])
C0040038 (UMLS CUI [2])
Medical contraindication
Item
presenting with a general or visceral contraindication (uncontrolled or severe cardiovascular disease ; plasma creatinine concentration 2 times greater than the upper limit of laboratory ranges ; aspartate aminotransferase (ast) or alanine aminotransferase (alt) levels, 3.5 times greater than the upper limit of laboratory ranges ; patient presenting evolutive cancer other than aml, except in situ basal-cell carcinoma or in situ cervix cancer ; severe evolutive infection, or, hiv seropositive or, active hepatitis related to b or c viral infection)
boolean
C1301624 (UMLS CUI [1])
Transfusion Reaction
Item
History of grade 3 transfusional incident
boolean
C0274435 (UMLS CUI [1])
Hypersensitivity
Item
Has known or suspected hypersensitivity or intolerance to mannitol
boolean
C0020517 (UMLS CUI [1,1])
C0024730 (UMLS CUI [1,2])
C0024730 (UMLS CUI [1,2])
Contraindication to cytarabine
Item
Patient presenting contraindication to cytarabine treatment
boolean
C1301624 (UMLS CUI [1,1])
C0010711 (UMLS CUI [1,2])
C0010711 (UMLS CUI [1,2])
Participation in other study
Item
Participation in an investigational drug study within the 30 days prior to entry
boolean
C2348568 (UMLS CUI [1])